Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Safety and Pharmacokinetics of LP002 (a Humanized Monoclonal Antibody Targeting PD-L1) in Patients With Malignant Digestive System Neoplasms

X
Trial Profile

A Phase I Study of Safety and Pharmacokinetics of LP002 (a Humanized Monoclonal Antibody Targeting PD-L1) in Patients With Malignant Digestive System Neoplasms

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LP 002-Lepu Biopharma (Primary) ; Cisplatin; Fluorouracil; OH 2
  • Indications Adenocarcinoma; Carcinoma; Digestive system neoplasms; Gastric cancer; Neuroendocrine tumours; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Taizhou HoudeAoke Biomedical
  • Most Recent Events

    • 07 Jun 2022 Results (n=30) assessing safety and pathological response of gastroesophageal cancer pts receiving LP002, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Feb 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top